반응식
[CH:1]1([C:4]2[C:5]([O:13][CH2:14][C:15]([F:18])([F:17])[F:16])=[CH:6][C:7]([C:10]([OH:12])=O)=[N:8][CH:9]=2)[CH2:3][CH2:2]1.[C:19]([O:23][C:24](=[O:31])[CH:25]([NH2:30])[C:26]([CH3:29])([CH3:28])[CH3:27])([CH3:22])([CH3:21])[CH3:20]>>[CH:1]1([C:4]2[C:5]([O:13][CH2:14][C:15]([F:18])([F:17])[F:16])=[CH:6][C:7]([C:10]([NH:30][CH:25]([C:26]([CH3:29])([CH3:28])[CH3:27])[C:24]([O:23][C:19]([CH3:21])([CH3:20])[CH3:22])=[O:31])=[O:12])=[N:8][CH:9]=2)[CH2:2][CH2:3]1참가 물질
3
실험 절차
The title compound was synthesized in analogy to Example 112e, using 5-Cyclopropyl-4-(2,2,2-trifluoro-ethoxy)-pyridine-2-carboxylic acid (Example 48c) and 2-Amino-3,3-dimethyl-butyric acid tert-butyl ester (CAN 99285-38-8) as starting materials and isolated (490 mg, 92%); MS (ESI, m/z): 431.6 (M+H+).
후처리
- customisolated (490 mg, 92%)
출처 및 근거
- ORD 기록
- ord-1fe1f5af62a44c1ca561a895c1511f76
- 출처 데이터셋
- uspto-grants-2016_08
- 특허 번호
- US09409866B2
연결된 노트
불러오는 중…